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ABSTRACT
The existing literature on serum insulin-like growth factor I
(IGF-I) levels in insulin-dependent diabetes mellitus (IDDM) is con-
flicting. Free IGF-I may have greater physiological and clinical rel-
evance than total IGF-I. Recently, a validated method has been de-
veloped to measure free IGF-I levels in the circulation.
Serum free and total IGF-I, IGF-binding protein-1 (IGFBP-1), and
IGFBP-3 levels were measured in 56 insulin-treated IDDM patients and
52 healthy sex- and age-matched controls. Diabetic retinopathy was
established by direct fundoscopy. In 54 IDDM patients, the glomerular
filtration rate (GFR) and effective renal plasma flow were calculated
from the clearance rate of [125I]iothalamate and [131I]iodohippurate
sodium.
Fasting free IGF-I, total IGF-I, and IGFBP-3 levels were signifi-
cantly lower in IDDM patients than in age- and sex-matched healthy
controls (free IGF-I, P , 0.005; total IGF-I, P , 0.001; IGFBP-3, P 5
0.001), whereas IGFBP-1 levels were higher (P , 0.001).
In IDDM subjects, decreases in free IGF-I, total IGF-I, and
IGFBP-3 levels with age were observed (free IGF-I, r 5 20.27 and
P 5 0.05; total IGF-I, r 5 20.52 and P , 0.001; IGFBP-3, r 5 20.37
and P 5 0.005). Free IGF-I was inversely related to fasting glucose
in IDDM subjects (r 5 20.35; P 5 0.01), whereas the relationship
between total IGF-I and fasting glucose did not reach significance
(r 5 20.27; P 5 0.06).
Age-adjusted free IGF-I levels were significantly higher (P , 0.05)
in IDDM subjects with retinopathy than in subjects without retinop-
athy after adjustment for age.
Total IGF-I and IGFBP-3 levels were positively related to GFR
(total IGF-I, r 5 0.35 and P , 0.05; IGFBP-3, r 5 0.28 and P , 0.05).
Both of these differences lost significance after adjustment for age.
Free IGF-I, total IGF-I, and IGFBP-3 levels were lower and IG-
FBP-1 levels were higher in insulin-treated IDDM subjects compared
to those in age- and sex-matched controls. Free IGF-I, total IGF-I, and
IGFBP-3 levels decreased significantly with age in IDDM subjects.
Age-adjusted free IGF-I levels in subjects with diabetic retinopathy
were higher than those in subjects without diabetic retinopathy. Total
IGF-I and IGFBP-3 levels were positively related to GFR in IDDM
subjects, but these relations were lost after adjustment for age. Mea-
surement of serum free IGF-I levels in IDDM subjects did not have
clear advantages compared to that of total IGF-I, IGFBP-1, and IG-
FBP-3 levels. Serum IGF-I and IGFBPs reflect their tissue concen-
trations to a various degree. Consequently, extrapolations concerning
the pathogenetic role of the IGF/IGFBP system in the development of
diabetic complications at the tissue level remain speculative. (J Clin
Endocrinol Metab 82: 2809–2815, 1997)
THE LITERATURE on insulin-like growth factor I (IGF-I)in patients with diabetes is conflicting. Flyvbjerg re-
ported that in patients with insulin-dependent diabetes mel-
litus (IDDM) the serum levels of IGF-I were within the nor-
mal range for the entire population (aged 20–80 yr)
compared with age- and sex-matched controls (1). Therefore,
Lamberton et al. concluded that serum IGF-I, measured as
total IGF-I levels, probably does not play an important role
in the pathogenesis of diabetic microvascular disease (2). On
the other hand, Merimee et al. reported a transient rise in total
serum IGF-I levels in patients with diabetes mellitus in the
early phase of neovascularization of the retina (3). These
findings could not be confirmed by Hyer et al. (4) or Wang
et al. (5).
Blood-borne IGF-I may also contribute to the glomerular
hyperfiltration observed in early diabetic nephropathy (6).
However, circulating levels of total IGF-I do not closely cor-
relate to renal hypertrophy, and there is a lack of correlation
between kidney size and the progressive decline in the glo-
merular filtration rate (GFR) in diabetic patients, suggesting
that factors important for growth might not necessarily be
involved in renal hemodynamics (7, 8).
Part of the controversy concerning serum IGF-I levels in
IDDM may be explained by methodological problems in the
IGF-I assay. Until recently, the assay methods used to mea-
sure IGF-I in serum were not able to distinguish among
unbound, free IGF-I, and IGF-I bound to binding proteins
(IGFBPs) (9). IGFBP-3 appears to be the primary regulator of
IGF levels in response to changes in circulating GH levels and
serves as a storage pool for IGF-I (10), whereas IGFBP-1
appears to be the primary regulator of IGF-I levels in re-
sponse to changes in circulating insulin levels (11).
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Determination of free IGF-I instead of total IGF-I might be
a way to gain insight into the concentrations and the role of
the IGF-I/IGFBP system in IDDM (7). Free IGF-I, by analogy
with sex and adrenal steroids and thyroid hormones, may be
the major biologically active, hormonal form of IGF-I (12).
Here we report the results of a study in which we inves-
tigated the relationships of circulating free IGF-I, total IGF-I,
IGFBP-1, and IGFBP-3 levels to GH release and to the pres-
ence of diabetic retinopathy and renal hemodynamics in
patients with IDDM.
Subjects and Methods
Subjects
The study group consisted of 56 consecutive patients with IDDM who
visited our out-patient clinic. Inclusion criteria were IDDM, age 18 yr or
older at the time of the study, age at diagnosis below 40 yr and insulin
dependency within 6 months of diagnosis, no other medication than
insulin, glycosylated hemoglobin (HbA1c) less than 11%, normal serum
creatinine (50–110 mmol/L), and no overt nephropathy (albuminuria,
,300 mg/24 h in 2 of 3 measurements). About half of these patients were
part of a previous study in which the dynamics of GH secretion were
studied (13). All patients were on an insulin dose schedule of 2–4 times
daily, using combinations of short-acting and intermediate long-acting
insulin. Fifty-two age- and sex-matched controls without evidence of
disease were recruited from the normal urban population and staff
members of our hospital to measure free and total IGF-I levels. The study
was approved by the hospital ethical review committee, and all patients
and volunteers gave their informed consent.
Blood sampling
Blood was collected between 0800–0900 h in the morning after an
overnight fast in both IDDM patients as well as the control group. The
last insulin injection on the day before blood sampling was administered
at 2200 h by IDDM subjects receiving intensive insulin therapy (four
daily injections, injection of an intermediate long-acting insulin at
2200 h) and at 1800 h by IDDM subjects receiving conventional therapy
(two daily injections of a mixture of short- and medium-acting insulins).
Hemodynamic and renal function tests
In 54 of 56 subjects with IDDM, renal and hemodynamic function tests
were performed. The GFR and effective renal plasma flow (ERPF) were
calculated from the clearance of [125I]iothalamate and [131I]iodohippu-
rate sodium, respectively, as described in detail previously (14). Blood
glucose measurements were performed every 30 min. Glucose (50 mg/
kgzh) and insulin (daily dose in units divided by 100/h) was given iv.
To maintain the blood glucose concentration between 6.0–10 mmol/L,
the rate of glucose infusion was adjusted according to the blood glucose
levels. The mean GFR in a group of normal subjects (n 5 18, 10 men and
8 women; mean age, 39 yr; range, 25–61 yr) was 107 (range, 88–130)
mL/minz1.73 m2. A GFR greater than 130 mL/minz1.73 m2 indicated
hyperfiltration.
Blood pressure was measured every 5 min during a 60-min period in
the supine position using an automatic device (Datascope, Accutor 1a,
Parasmus, NJ). The mean of at least six values between 30–60 min was
calculated.
Analytical methods
The free IGF-I immunoradiometric assay (Diagnostics System Lab-
oratories, Webster, TX) used in the present study needs no sample
extraction. The assay has been previously described (15, 16). In short,
serum samples (100 mL) or recombinant human IGF-I standards were
added to tubes containing a dense coating of the primary high affinity
IGF-I antibody and incubated at 2 h at room temperature. No residual
IGFBP-1 or IGFBP-3 was detectable after the first wash according to the
manufacturer’s data (15). The tubes were washed and incubated for 2 h
at room temperature with the secondary radiolabeled antibody, washed
three times with deionized water, and counted. The lower limit of
detection is 4 pmol/L. The cross-reactivity with IGF-II is less than 0.01%.
The intra- and interassay coefficients of variation (CVs) for the free IGF-I
assay are 10.3% and 10.7%, respectively, at a plasma level of 0.01 nmol/L
(n 5 8).
Total IGF-I was determined by a commercially available RIA (Med-
genix Diagnostics, Brussels, Belgium; intra- and interassay CVs, 6.1%
and 9.9%). Immunoradiometric assays were used for the measurement
of IGFBP-1 and IGFBP-3 (Diagnostics System Laboratories; intra- and
interassay CVs for IGFBP-1, 5.2% and 6.0%; intra- and interassay CVs for
IGFBP-3, 0.56% and 1.9%). HbA1c was measured by high performance
liquid chromatography (normal range, 5.0–6.3%; Variant HPLC-Bio-
Rad, Veenendaal, The Netherlands), and blood glucose concentrations
were measured in venous whole blood by an automatic hexokinase
method (Boehringer Mannheim, Mannheim, Germany). Urinary albu-
min was measured with a radial immunodiffusion on agarose gel that
contained 0.4 mL antialbumin antiserum (Dako A 001, Dakopatts,
Copenhagen, Denmark) (17). The lower limit of detection was 2 mg/L,
and the interassay variability was 8%. The means of the results of three
collection periods are presented.
Diabetic retinopathy
Diabetic retinopathy (DRP) was established by direct fundoscopy, as
judged by an experienced ophthalmologist, and was graded as no DRP,
background DRP, or proliferative DRP (18).
Statistical analysis
Baseline clinical characteristics are presented as the mean and range.
Free IGF-I, total IGF-I, IGFBP-1, IGFBP-3, and urinary albumin excretion
have a log normal distribution and are, therefore, presented as the
geometric mean. IDDM subjects were compared with healthy controls.
For the healthy control group we did not match on an individual basis,
but performed frequency matching, i.e. selecting our controls in such a
way that age and sex distribution were similar in cases and controls. For
diabetic subgroups, mean and 95% confidence intervals are presented.
Baseline differences between variables were analyzed with one-way
ANOVA. Pearson’s partial correlation coefficients were calculated to
analyze the associations between variables and to test significance. Free
IGF-I, total IGF-I, IGFBP-1, and IGFBP-3 did not meet the criteria for
normality and were logarithmically transformed before analysis. After
this transformation, a normalization of the distribution was achieved.
The results presented in Table 3 were adjusted for age using linear
regression analysis with (total and free) IGF-I, IGFBP-1, and IGFBP-3 as
dependent variables and age and retinopathy (yes/no) as independent
variables. The relations between total IGF-I and IGFBP-3, respectively,
and GFR were adjusted for age using linear regression analysis with total
IGF-I and IGFBP-3 as dependent variables and age and GFR as inde-
pendent variables. Two-sided P , 0.05 was considered significant. All
statistical analyses were performed with Stata statistical package (Com-
puting Resource Center, Santa Monica, CA).
Results
General characteristics
The baseline clinical characteristics of 56 IDDM subjects
(23 women and 33 men) are presented in Table 1. In the 52
sex- and age-matched controls, the female/male ratio was
21/31 and not significantly different from that in the IDDM
patients. The mean age in the control group was 34.5 yr (sd,
13.8; range, 18–64) and did not differ from that in the IDDM
group. Twenty-two of the 54 IDDM patients had a GFR above
130 mL/minz1.73 m2 and were classified as hyperfiltrators.
Serum free and total IGF-I levels in the IDDM patients and
control subjects are shown in Fig. 1 and Table 2. Serum free
and total IGF-I levels were significantly lower in the IDDM
patients than in the control group. The ratio between free
IGF-I and total IGF-I levels was lower, but not statistically
different, between IDDM patients and healthy controls.
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Serum IGFBP-3 levels were significantly lower and IGFBP-1
significantly higher in the IDDM patients than in the control
group (Fig. 1 and Table 2).
Free IGF-I serum levels were positively related to the total
IGF-I concentration (IDDM, r 5 0.52 and P , 0.001; control
group, r 5 0.47 and P , 0.001) and IGFBP-3 (IDDM, r 5 0.33
and P , 0.05; control group, r 5 0.19 and P 5 0.17) and
inversely related to the IGFBP-1 concentration (IDDM, r 5
20.40 and P , 0.005; control group, r 5 20.47 and P , 0.001).
The plasma concentration of total IGF-I was positively re-
lated to IGFBP-3 (IDDM, r 5 0.72 and P , 0.001; control
group, r 5 0.47 and P , 0.001) and inversely to IGFBP-1 levels
(IDDM, r 5 20.42 and P , 0.005; control group, r 5 20.56
and P , 0.001).
Both free IGF-I as well as IGFBP-3 levels decreased sig-
nificantly with age in diabetic patients, whereas IGFBP-1
levels did not change with age (Fig. 2, B and C). In the normal
individuals such decreases in free IGF-I and IGFBP-3 with
age were not statistically significant (Fig. 2, B and C), whereas
total IGF-I levels were inversely related to age in both IDDM
and healthy controls (Fig. 2A). Free IGF-I and IGFBP-3 levels
tended to be disproportionately lower in IDDM than healthy
controls with increasing age (Fig. 2, B and C).
Free IGF-I was inversely related to fasting glucose in
IDDM subjects, but not to HbA1c (Fig. 3). The relation be-
tween total IGF-I and fasting glucose did not reach signifi-
cance (r 5 20.27; P 5 0.06), and fasting IGFBP-1 levels were
positively related to fasting glucose levels in IDDM subjects
FIG. 1. Free (A) and total (B) IGF-I, IGFBP-1 (C), and IGFBP-3 (D) levels in IDDM subjects (left) and healthy controls (right). Note the
logarithmic scale of the vertical axes. The bar represents the median value in each group.
TABLE 1. Clinical characteristics of patients with IDDM
Mean Range
Age (yr) 36.3 18–63
BMI (kg/m2) 23.8 16.1–37.9
Duration of diabetes (yr) 17.6 3–44
Fasting glucose (mmol/L) 10.5 3.2–19.6
Hemoglobin A1c (%) 8.7 5.4–10.5
Serum creatinine (mmol/L) 79 50–119
Albuminuria (mg/24 h) 12 2–167
Systolic blood pressure (mm Hg) 130 100–197
Diastolic blood pressure (mm Hg) 75 60–101
Insulin dose (IU/day) 53 30–78
GFR (mL/minz1.73 m2) 126 59–206
ERPF (mL/minz1.73 m2) 554 298–917
Retinopathy (no. of patients)
None 29
Background 13
Proliferative 14
Results are presented as arrythmic mean and range; albumin is
expressed as geometric mean and range, BMI, Body mass index was
defined as weight (kilograms) divided by the square of height
(meters); GFR, glomerular filtration rate; ERPF, effective renal
plasma flow.
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(Fig. 3). Fasting glucose levels were positively related to
HbA1c (r 5 0.36; P 5 0.01).
IGF-I/IGFBP system in IDDM patients with retinopathy
The 27 IDDM patients with retinopathy were older than
the 29 patients without retinopathy, the duration of diabetes
was longer, blood pressure was higher, and the GFR and
ERPF were lower (Table 3). Free and total IGF-I, IGFBP-1,
IGFBP-3, HbA1c and fasting glucose levels were not different
between the 2 groups. When adjusted for age, the patients
with retinopathy tended to have higher free IGF-I levels (P 5
0.04).
Renal hemodynamics
Using 130 mL/minz1.73 m2 as a cut-off, 22 patients had
hyperfiltration, and 32 had a normal GFR (Table 4). The
patients with hyperfiltration were younger, and blood pres-
sure was not different in the two groups. In IDDM subjects,
GFR decreased significantly with age (r 5 20.53; P , 0.001).
Free IGF-I, IGFBP-1, and IGFBP-3 levels tended to be higher
TABLE 2. Comparison of fasting total and free IGF-I, IGFBP-I, and IGFBP-3 levels between IDDM patients and (age- and sex-matched)
healthy controls
IDDM Controls
P valuea
Mean Range Mean Range
Free IGF-I (nmol/L) 0.09 0.01–0.57 0.15 0.04–0.58 ,0.005
Total IGF-I (nmol/L) 19.4 6.9–44.3 27.6 13.3–51.4 ,0.001
Free IGF-I over total IGF-I ratio 3 100% 0.59 0.11–1.99 0.67 0.13–2.37 NS
IGFBP-1 (nmol/L) 4.1 0.4–35.3 0.78 0.08–5.46 ,0.001
IGFBP-3 (nmol/L) 99.0 50.2–163.3 114.6 79.6–170.7 50.001
Results are expressed as the geometric mean and range. The results of the free IGF-I/total IGF-I are presented as the mean.
a By ANOVA.
FIG. 2. Relation between age and total IGF-I levels (A), free IGF-I levels (B), and IGFBP-3 levels (C), respectively, in healthy controls (top) and
IDDM patients (bottom) matched for age and sex. Note the logarithmic scale of the vertical axes.
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in the IDDM patients with hyperfiltration than in subjects
with a GFR below 130 mL/minz1.73 m2 (Table 4), but the
differences were not significant.
Total IGF-I and IGFBP-3, but not free IGF-I, levels were
positively related to GFR (r 5 0.35 and P , 0.05, and r 5 0.28
and P , 0.05, respectively). The relationships between total
IGF-I and IGFBP-3 levels and GFR were lost after adjustment
for age.
After adjustment for fasting glucose, IGFBP-1 levels were
inversely related to GFR (r 5 20.30; P , 0.05). Total and free
IGF-I levels were not related to ERPF.
Discussion
There are many contradictory studies of IGF-I in patients
with diabetes, and the methodologies used are highly vari-
able, even between studies with similar findings. Some stud-
ies have previously found low total IGF-I and IGFBP-3 levels
and high fasting IGFBP-1 levels in IDDM despite hyperse-
cretion of GH (19–21). Our study shows that the fasting
serum levels of total IGF-I (the sum of free IGF-I and IGF-I
bound to an array of IGFBPs) and IGFBP-3 are lower, and
IGFBP-1 levels are higher in insulin-treated IDDM patients
than in an age- and sex-matched healthy control group. We
also observed lower fasting free IGF-I levels in adult IDDM
patients despite insulin treatment. It is likely that the free
IGF-I levels measured in our study represent a combination
of the true free IGF-I levels and a fraction of IGF-I that can
be readily dissociated from IGFBPs under the specific assay
conditions (15). Recently, free IGF-I concentrations were
found to be low in untreated IDDM children using the same
assay, but these concentrations tended to normalize after the
start of insulin treatment (22).
We observed a significant decrease in free IGF-I and IG-
FBP-3 levels during aging in IDDM subjects, but not in our
healthy control population. Therefore, free IGF-I and IG-
FBP-3 levels tended to be disproportionately lower in IDDM
than in our healthy controls. A difference between IDDM
subjects and healthy controls was not observed for total IGF-I
levels with increasing age. In accordance with this, Graubert
et al. reported that in the streptozocin-induced diabetic rat,
serum free IGF-I concentrations were more depressed than
FIG. 3. Relation between fasting glucose levels and free IGF-I (upper
panel), total IGF-I (center panel), and IGFBP-1 (lower panel) levels,
respectively, in IDDM subjects. Note the logarithmic scale of the
horizontal axes.
TABLE 3. Serum free IGF-I levels and other clinical characteristics of diabetic patients with and without clinically manifest diabetic
retinopathy
No retinopathy (n 5 29) Retinopathya
P valueb
Mean 95% CI Mean 95% CI
Free IGF-I (nmol/L)c 0.09 0.04–0.20 0.10 0.04–0.23 NS
Total IGF-I (nmol/L)c 21.2 10.0–45.1 17.6 8.3–37.3 NS
IGFBP-1 (nmol/L)c 3.98 2.85–5.57 4.22 2.86–6.22 NS
IGFBP-3 (nmol/L)c 104.4 94.8–115.1 93.5 84.6–103.3 NS
Age (yr) 29.1 25.3–33.0 44.1 39.7–48.5 ,0.001
Duration of diabetes (yr) 12.4 10.4–14.5 23.2 19.4–27.0 ,0.001
Systolic blood pressure (mm Hg) 125 120–130 134 127–143 ,0.05
Diastolic blood pressure (mm Hg) 73 69–77 77 73–81 NS
Serum creatinine (mmol/L) 75 70–80 83 74–91 NS
GFR (mL/minz1.73 m2) 140 131–148 111 102–121 ,0.001
ERPF (mL/minz1.73 m2) 594 557–631 514 473–555 ,0.005
Albuminuria (mg/24 h)c 10 4–23 16 6–41 NS
Fasting glucose (mmol/L) 10.67 8.87–12.48 10.27 8.24–12.29 NS
Hemoglobin A1c (%) 8.77 8.21–9.33 8.57 8.07–9.06 NS
Insulin dose (IU/day) 55 50–60 52 46–58 NS
BMI (kg/m2) 24.0 21.9–26.2 24.5 22.7–26.3 NS
For abbreviations, see Table 1.
a n 5 27; 13 background and 14 proliferative.
b By ANOVA, comparing subjects with and without retinopathy; P , 0.05 was considered statistically significant.
c Geometric mean.
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total IGF-I (23). Reduced free IGF-I concentrations probably
account for the reduced IGF-I bioactivity in diabetic serum,
as reported in earlier studies (24).
Free IGF-I levels were inversely related to fasting glucose
levels in IDDM subjects, whereas fasting glucose levels were
positively related to HbA1c. IGF-I exerts a tonic hypoglyce-
mic effect in the circulation (25), and decreased IGF-I levels
may induce an increase in serum glucose levels. As we ob-
served a significant decrease in free IGF-I levels during aging
in IDDM subjects, this decrease might contribute to gradu-
ally higher serum glucose levels and thereby to the devel-
opment of diabetic microvascular complications (26).
IGFBP-1 levels were positively related to fasting glucose
levels. A previous study in IDDM subjects also reported a
positive relationship between IGFBP-1 and fasting plasma
glucose levels (27). IGFBP-1 administration causes an acute
rapid increase in plasma glucose levels (25), which suggests
that increased IGFBP-1 levels result in decreased availability
of free IGF-I levels (28). IGFBP-1 is thought to modulate the
free fraction of IGF-I. The inverse relationship between free
IGF-I and IGFBP-1 in our study supports the hypothesis that
circulating free IGF-I levels are low(er) when IGFBP-1 levels
are high (15).
Free IGF-I levels tended to be higher in IDDM patients
with retinopathy after adjustment for age. However, this
result needs to be interpreted with caution because retinop-
athy scoring was performed with direct ophthalmoscopy, a
technique that may result in some misclassification of sub-
jects and could, therefore, materially alter the results and the
conclusions of our study.
An increased GFR is considered an early symptom in
diabetes mellitus (29). We observed lower values for total
serum IGF-I in IDDM patients than in sex- and age-matched
controls, which suggests at first glance no important role for
IGF-I in the pathogenesis of hyperfiltration in IDDM. Nev-
ertheless, in our study total IGF-I levels were positively re-
lated to the GFR. The observed correlation coefficient be-
tween total IGF-I and GFR is in agreement with previous data
showing that IGF-I leads to an augmentation of GFR by
10–20% (30, 31). In an experimental animal model of diabetes
that was characterized by increased GFR, increased binding
of IGF-I to its renal IGF-I receptors was found compared to
that in controls (32). Increased binding of IGF-I to the IGF-I
receptor in the IDDM subjects despite low serum total IGF-I
levels might also explain the observed relationship between
total IGF-I and GFR in our study. However, this relationship
was lost after adjustment for age, which suggests that the
relationship between GFR and serum total IGF-I levels is age
dependent and lost after the physiological age-dependent
decrease in serum total IGF-I levels with aging.
In conclusion, free and total IGF-I and IGFBP-3 levels are
lower and IGFBP-1 levels are higher in IDDM subjects than
in controls. Free IGF-I and IGFBP-3 levels decrease signifi-
cantly with age in IDDM subjects between 20–65 yr of age.
Higher (age-adjusted) free IGF-I levels were observed in
IDDM subjects with diabetic retinopathy than in subjects
without retinopathy, but this difference was lost after further
adjustment for glucose levels. Total IGF-I and IGFBP-3 levels
were related to GFR in IDDM subjects, but this relation was
lost after adjustment for age.
Measurement of serum free IGF-I levels in IDDM subjects
did not provide clear advantages compared to that of total
IGF-I, IGFBP-1, and IGFBP-3 levels. Serum IGF-I and IGFBPs
reflect their tissue concentrations to various degrees. Con-
sequently, extrapolations concerning the pathogenetic role of
the IGF-IGFBP system in the development of diabetic com-
plications at the tissue level remain speculative.
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For abbreviations, see Table 1.
a ANOVA, comparing subjects with and without hyperfiltration; P , 0.05 was considered statistically significant.
b Geometric mean.
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